In SGLT-Is RCTs (6 trials, 124 strokes, 31,327 participants), the risk of fatal hemorrhagic and ischemic stroke did not decrease with SGLT2-Is use (RR: 0.89, 95% CI [0.62, 1.28], p = 0.54) vs. non-SGLT2-Is use (fixed and random effect models; Supplementary Figures S5, S6). Here, SLC5A2 is linked to stroke disorder.